- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | ArriVent BioPharma, Inc.: ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 17.03. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | ArriVent Biopharma, Inc. Full Year Loss Increases | 1 | RTTNews | ||
| 05.03. | ArriVent BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 05.03. | ArriVent BioPharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald | 5 | Investing.com | ||
| 16.01. | Cantor Fitzgerald bestätigt "Overweight"-Rating für ArriVent | - | Investing.com Deutsch | ||
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 06.01. | ArriVent BioPharma: Oppenheimer bestätigt "Outperform"-Rating und Kursziel von 44 US-Dollar | 3 | Investing.com Deutsch | ||
| 06.01. | Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock | 1 | Investing.com | ||
| 22.12.25 | Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating | 3 | Investing.com | ||
| 22.12.25 | ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug | 4 | Investing.com | ||
| 22.12.25 | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | 275 | GlobeNewswire (Europe) | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| 10.12.25 | ArriVent BioPharma: BTIG startet mit Kaufempfehlung wegen Onkologie-Potenzial | 2 | Investing.com Deutsch | ||
| 10.12.25 | ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential | 1 | Investing.com | ||
| 25.11.25 | ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug | 3 | Investing.com | ||
| 10.11.25 | ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street | 5 | Investing.com | ||
| 10.11.25 | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | ArriVent BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.09.25 | ArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial Officer | 394 | GlobeNewswire (Europe) | NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARTELO BIOSCIENCES | 10,510 | +229,47 % | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,250 | +11,58 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ONCONETIX | 1,890 | -41,30 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| ERASCA | 14,980 | -1,19 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| ARCELLX | 114,56 | -0,07 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| BIONTECH | 74,50 | -1,84 % | BioNTech nach den Turbulenzen: Was passiert jetzt mit dem Unternehmen? | Die Aktie von BioNTech wurde in den vergangenen Wochen ordentlich durchgeschüttelt. Insbesondere die Ankündigung, dass Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres die Gesellschaft verlassen... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,85 | -0,68 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,890 | -3,43 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 78,18 | -2,42 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting | ||
| ENLIVEN THERAPEUTICS | 38,900 | -0,70 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| STRUCTURE THERAPEUTICS | 45,900 | -0,80 % | Wolfe Research initiates Structure Therapeutics stock rating at Peerperform | ||
| CG ONCOLOGY | 64,67 | -2,90 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| ZENAS BIOPHARMA | 18,275 | -17,53 % | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | ||
| ALUMIS | 24,840 | -5,62 % | Alumis reports Phase 3 psoriasis trial results for envudeucitinib |
ARRIVENT BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,410 (-1,88 %) liegt der Kurs bei 21,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.